- Record: found
- Abstract: found
- Article: not found
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells
1 ,
Bruce G Robinson ,
Robert F Gagel ,
Henning Dralle ,
James A Fagin ,
Massimo Santoro ,
Eric Baudin ,
Rossella Elisei ,
Barbara Jarzab ,
James R Vasselli ,
Jessica Read ,
Peter Langmuir ,
Anderson J Ryan ,
Martin J Schlumberger
Jan 10 2012
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.